Literature DB >> 20850423

Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study.

Nikolaos P E Kadoglou1, Argirios Gkontopoulos, Alkistis Kapelouzou, Grigorios Fotiadis, Efstratios K Theofilogiannakos, George Kottas, Stilianos Lampropoulos.   

Abstract

BACKGROUND: The association of novel adipokines, vaspin and visfatin, with atherosclerosis is still obscure. The present study aimed to investigate the relationship of those adipokines with the existence as well as the extent of coronary artery disease (CAD), suggesting a link between adiposity and atherosclerosis.
METHODS: We enrolled a total of 108 patients with angiographically proven stable, asymptomatic CAD and 65 healthy controls (HC) without cardiovascular diseases. The severity of CAD was assessed using coronary angiography by the Gensini score. Clinical parameters, glycemic and lipid profile, high-sensitivity CRP (hsCRP), vaspin and visfatin levels were assayed.
RESULTS: Serum levels of vaspin were significantly lower in subjects with CAD [0.91 (0.44-1.29) ng/ml] than healthy controls [1.42 (0.96-2.42) ng/ml] (p = 0.009). Inversely, visfatin (p = 0.016) and hsCRP (p < 0.001) levels were considerably up-regulated in CAD vs HC group. Multivariate analysis demonstrated decreased vaspin and increased visfatin levels to correlate with CAD presence, independent of other cardiovascular risk factors (p < 0.05). Standard multiple regression revealed HDL, LDL-C and vaspin to be independent determinants of Gensini score (R² = 0.189, p = 0.019). Notably, statin-free patients had even lower vaspin levels compared to statin users (p = 0.018).
CONCLUSIONS: Decreased vaspin and increased visfatin serum levels were observed in asymptomatic patients with CAD. Low vaspin concentrations seemed to correlate with CAD severity.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20850423     DOI: 10.1016/j.cca.2010.09.012

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  29 in total

1.  Mechanistic insights into the link between visfatin gene C-1535T polymorphism and coronary artery disease: an in vitro study.

Authors:  Yong-Sheng Wang; Wei Gao; Hong-Fen Li; Ze-Mu Wang; Jun Zhu; Huan Zhao; Jian-Jun Yan; En-Zhi Jia; Zhi-Jian Yang; Lian-Sheng Wang
Journal:  Mol Cell Biochem       Date:  2011-12-07       Impact factor: 3.396

Review 2.  Vaspin in obesity and diabetes: pathophysiological and clinical significance.

Authors:  Matthias Blüher
Journal:  Endocrine       Date:  2011-12-03       Impact factor: 3.633

3.  Circulating levels of apelin, glucagon-like peptide and visfatin in hypercholesterolemic-hyperhomocysteinemic guinea-pigs: their relation with NO metabolism.

Authors:  Zeynep Kusku-Kiraz; Sema Genc; Seldag Bekpinar; Yesim Unlucerci; Vakur Olgac; Mujdat Uysal; Figen Gurdol
Journal:  Mol Cell Biochem       Date:  2014-11-08       Impact factor: 3.396

4.  Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes.

Authors:  Faramarz Darabi; Mahmoud Aghaei; Ahmad Movahedian; Armin Elahifar; Ali Pourmoghadas; Nizal Sarrafzadegan
Journal:  Heart Vessels       Date:  2016-10-26       Impact factor: 2.037

5.  High serum vaspin concentrations in patients with ulcerative colitis.

Authors:  Tomohito Morisaki; Fuminao Takeshima; Hiroko Fukuda; Kayoko Matsushima; Yuko Akazawa; Naoyuki Yamaguchi; Ken Ohnita; Hajime Isomoto; Hiroaki Takeshita; Terumitsu Sawai; Fumihiko Fujita; Kazuhiko Nakao
Journal:  Dig Dis Sci       Date:  2013-10-29       Impact factor: 3.199

Review 6.  The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines.

Authors:  John Palios; Nikolaos P E Kadoglou; Stylianos Lampropoulos
Journal:  Exp Diabetes Res       Date:  2011-12-08

7.  The investigation of serum vaspin level in atherosclerotic coronary artery disease.

Authors:  Mehmet Ali Kobat; Ahmet Celik; Mehmet Balin; Yakup Altas; Adil Baydas; Musa Bulut; Suleyman Aydin; Necati Dagli; Mustafa Ferzeyn Yavuzkir; Selcuk Ilhan
Journal:  J Clin Med Res       Date:  2012-03-23

8.  Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells.

Authors:  Chang Hee Jung; Woo Je Lee; Jenie Yoonoo Hwang; Min Jung Lee; So Mi Seol; Yun Mi Kim; Yoo La Lee; Hyun Sik Kim; Min-Seon Kim; Joong-Yeol Park
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

9.  Effect of statin therapy on vaspin levels in type 2 diabetic patients.

Authors:  Sayer I Al-Azzam; Karem H Alzoubi; Jaafar Abu Abeeleh; Nizar M Mhaidat; Mahmoud Abu-Abeeleh
Journal:  Clin Pharmacol       Date:  2013-02-20

10.  Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects.

Authors:  Pedro Saddi-Rosa; Carolina Oliveira; Felipe Crispim; Fernando M A Giuffrida; Valter de Lima; José Vieira; Alessandro Doria; Gilberto Velho; André Reis
Journal:  Cardiovasc Diabetol       Date:  2013-08-22       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.